HAVCR2 and breast carcinoma: Anti-Tim-3 antibody promotes CXCL9 expression by these DCs, which enhances the function of CD8+ T cells and thereby improves paclitaxel’s therapeutic effect in breast cancer murine models of triple-negative and luminal B diseases.